For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...

A recent real-world study provides new evidence addressing this challenge. In this retrospective analysis, patients with PD-L1-low (CPS < 5) advanced G/GEJ cancer received first-line therapy with ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...

The Jem And The Holograms comic book series from IDW Publishing that ran from 2015 to 2017 is to be repackaged and republished by Boom Studios into a series of four digest graphic novels, the size and ...

LG just revealed several new speakers in the xboom line ahead of CES 2026. These speakers are part of an ongoing collaboration with will.i.am from Black Eyed Peas, who is on board as the "experimental ...

View post: REI Has a 'Comfortable' Rain Jacket on Sale for Almost 50% Off With this online-only deal we found at Walmart, you can get the Goovi Portable Car Jump Starter for just $36, a massive 71% ...

STK-012 is an α/β biased IL-2 partial agonist designed to stimulate antigen-activated T cells while avoiding IL-2 associated toxicities Positive Phase 1b data recently presented at SITC 2025, with a ...

STK-012 is an α/β biased IL-2 designed to specifically stimulate antigen activated T cells Results from an ongoing Phase 1a/1b to be presented at SITC Company will also present new preclinical data on ...

New College of Florida wants to be the first university to sign the Trump administration’s compact for higher education, which would require institutions to make a number of changes to their policies ...